Background: The study aimed to determine whether a patient's choice for their intrathecal morphine (ITM) dose reflects their opioid requirements and pain after caesarean delivery and if giving women a choice of ITM dose would reduce opioid use and improve pain scores compared with women who did not have a choice. Methods: A total of 120 women undergoing caesarean delivery with spinal anaesthesia were enrolled in this randomized, double-blind study. Patients were randomly assigned to a choice of 100 or 200 lg ITM or no choice. The study involved deception, such that all participants were still randomly assigned 100 or 200 lg ITM regardless of choice. Rescue opioid use over the 48-h study period was the primary outcome measure. Pain at rest and movement and side effect (pruritus, nausea, and vomiting) data were collected 3, 6, 12, 24, 36 and 48 h postoperatively. Data are presented as median [95% confidence interval (CI)]. Results: Women who requested the larger ITM dose required more supplemental opioid [median 0.8 (95% CI 0.4-1.3)] mg morphine equivalents at each assessment interval; P < 0.001] and reported more pain with movement [median 1.2 (95% CI 0.5-1.9)] verbal numerical rating score of 0-10 points] than patients who requested the smaller ITM dose (P ¼ 0.0008), regardless of the ITM dose given. There was no difference in opioid use whether the patient was offered a perceived choice or not. Conclusions: Women who were given a choice and chose the larger ITM dose correctly anticipated a greater postoperative opioid requirement and more pain compared with women who chose the smaller dose. Simply being offered a choice did not impact opioid use or pain scores after caesarean delivery. Trial Registration: ClinicalTrials.gov (NCT01425762).
Pain after caesarean delivery (CD) is described as moderate to severe and is often incompletely relieved by modern pain management protocols. 1 Women with severe acute post-CD pain have an increased risk of persistent incisional pain compared with those who report mild acute postoperative pain. 2 With >1.4 million CDs now performed annually in the USA, strategies to reduce adverse maternal outcomes, including postoperative pain, have important clinical and public health implications. Analgesic drug dosing requires offsetting desired analgesic effects against expected drug-related side effects. The traditional physician-oriented models require the clinician to use standardized 'one-size-fits-all' pain management protocols or their expert opinion to select analgesic doses without soliciting patient input to guide the balance between analgesia and potential opioid-related side effects. Intrathecal morphine (ITM) is a very effective postoperative analgesic strategy utilized in the majority of women undergoing CD in the USA. 3 However, there is considerable heterogeneity among expectant women's desires for pain relief and potential side effect avoidance after CD. 4 A study found that simply asking patients preoperatively about anticipated pain, expected pain medication needs, and anxiety accounted for 20% of the variability in post-caesarean pain. 5 Effective pain management is an essential element of postoperative outcome; the Joint Commission recommends postoperative pain score of not >3 out of 10, both at rest and with movement. The patient's involvement in analgesic drugs and dosage selection based on individual desires for pain relief after surgery and concern for side effects may potentially improve the alignment between patient expectation and outcome. The primary aim of the study was to investigate whether a patient's choice for their ITM dose would be reflective of their CD pain and postoperative opioid analgesic use. We hypothesized that giving women a choice to select their ITM would have a positive analgesic effect and that women would be able to anticipate their analgesic needs such that those preferring a larger ITM dose would have higher postoperative analgesic requirements and greater pain scores. Secondary outcomes included side effect differences between women preferring a lower compared with a higher dose, as well as pain scores, opioid requirements, and side effect differences between the 100 and 200 lg ITM doses received.
Methods

Study design, setting, and sample population
The study was a prospective, randomized, double-blind, singlecentre study of 120 women undergoing CD. After approval by the Stanford University Institutional Review Board (Stanford, CA, USA), we approached consecutive patients who fulfilled study criteria to participate. Patients were invited to take part in the study if they were scheduled for CD with spinal anaesthesia and were 18-45 yr of age with a singleton, term (>37-weeks gestation) pregnancy. Written informed consent was obtained from all women who agreed to participate. The consent informed participants that they would be randomized to a choice or a no choice group. The 'no-choice" group was informed they would be randomized to a group that would receive either 100 or 200 lg ITM. The 'perceived-choice' group was not told they would be still randomized to receive either 100 or 200 lg ITM. Deception in the choice group could obviously not be disclosed in the consent, however, all participants received a debriefing letter after the study to explain the study design and that deception was used. Before patient enrolment, the study was registered on August 25, 2011, at http://www.clinicaltrials.gov (NCT01425762).
A history of significant medical or obstetric disease; contraindication to neuraxial anaesthesia; failed neuraxial anaesthesia requiring conversion to general anaesthesia; chronic pain, anxiety, or depression; use of antidepressants or anticonvulsants during the pregnancy; and intolerance or allergy to opioids, non-steroidal anti-inflammatories, or local anaesthetics were exclusion criteria. Subjects were also excluded who had taken opioids, acetaminophen, or non-steroidal antiinflammatory drugs within 48 h of surgery. Women were enrolled at their preoperative anaesthetic evaluation before their CD and written informed consent was obtained. The study was conducted at Stanford Children's Hospital, Palo Alto, CA, USA from August 2011 to August 2013 and was stopped when the pre-stated sample size was enrolled.
The study involved two potential doses (100 and 200 lg) of ITM for postoperative pain management. Using a computergenerated list of random numbers, we assigned patients to one of two groups: perceived choice and no choice. In the perceivedchoice group, patients were offered a choice of 100 or 200 lg ITM after being read a standardized script that discussed the tradeoff of pain relief after their CD with a possible increased risk of the most common opioid-related side effects-nausea, vomiting, and pruritus (appendix). However, the study involved deception such that the patient's choice was recorded but did not influence the actual dose of ITM administered. Instead, patients in the perceived-choice group were randomly assigned 100 or 200 lg of ITM. In the no-choice group, the patients were not offered a choice of ITM dose, and similarly received a randomly assigned dose of 100 or 200 lg of ITM. Figure 1 shows the enrolment and randomization diagram. Randomization was done before study commencement using the Excel (Microsoft, Redmond, WA, USA) random number generation function by an investigator not involved in enrolment. Simple randomization without stratification was utilized. Group assignments were contained in opaque envelopes to ensure blinding of the investigators. Patients, study investigators, and data analysts were blinded to group assignments. The anaesthesiologists administering the anaesthesia were not involved in data acquisition or analysis. The physician caring for the patient had no knowledge of the dose selection or group assignment (perceived choice vs. no choice). The Stanford University Institutional Review Board approved the use of deception as part of the study methodology. The aims of the study could not be accomplished without the use of deception, and the Institutional Review Board agreed that deception posed minimal risk to the patients. Patients were not informed at enrolment or during the study that deception was being utilized, as this knowledge would have potentially confounded the study results. After the study was completed and the data analysed, debriefing letters were sent to all patients who were deceived as part of the study design explaining the study methodology and use of deception.
Study protocol
All patients received spinal anaesthesia with intrathecal hyperbaric bupivacaine 12 mg, fentanyl 10 lg, and morphine 100 or 200 lg ITM as per randomization. The 100 and 200 lg ITM doses Editor's key points
• The relationship between patient expectation of analgesic need and actual pain relief required is unclear.
• This study explored how choice (high-or low-dose morphine) or no choice affected pain.
• A higher dose choice was associated with greater pain scores and analgesic consumption, regardless of the actual dose received.
• Concern for pain or side effects impacted how women chose an intrathecal morphine dose.
• Further work is needed to explore the use of patient involvement in improving postoperative analgesia.
had both been previously utilized at our institution and others. 6 Both ITM doses have been found to be efficacious, with the higher 200-lg dose providing slightly better analgesia, but with increased related side effects compared with the lower 100-lg dose. 6 Postoperative pain was managed according to a standardized postoperative pain management protocol. Oral ibuprofen 600 mg (or ketorolac 15 mg if nil per os) was administered every 6 h. Breakthrough pain was managed with oral hydrocodone 5 mg/acetaminophen 500 mg or oxycodone 5 mg/acetaminophen 325 mg. Women with pain verbal numerical rating scores (NRSs; 0 ¼ no pain and 10 ¼ worst pain imaginable) of 1-4 were offered one tablet (hydrocodone 5 mg or oxycodone 5 mg) every 4 h as needed, and those with pain NRSs >4 were offered two tablets (hydrocodone 10 mg or oxycodone 10 mg) every 4 h as needed. A maximum dose of 60 mg hydrocodone/oxycodone or 4 g acetaminophen was allowed in a 24-h period. I.V. morphine 4 mg (maximum 10 mg every hour) was reserved for severe pain or pain resistant to oral opioids.
Study outcome measures and endpoints
Demographic and obstetric data were recorded, including age, height, weight, gestational age, birthweight, education level, parity, and number of previous caesarean deliveries. The patients' reason for their ITM dose preference was recorded at the time of enrolment in the group offered a perceived choice. Options for women's primary reason for their dose selection preference included the following: previous experience with surgery was painful, previous experience with surgery was not painful, I usually am sensitive to painkillers and medications, I usually need more painkillers than other people, I am afraid of the drug transfer to my baby, I am afraid of nausea and vomiting after surgery, I am afraid of itching after surgery, I am afraid of pain after surgery, not sure, and other reasons. Women were allowed to pick more than one reason, and if they chose more than one reason they were asked to rank (1, 2, 3 . . .) the reasons in the order of importance (with 1 being most important).
Opioid use (oral and i.v.) was recorded at 3, 6, 12, 24, 36, and 48 h after CD and the total amount of supplemental opioid analgesic medication (oral and i.v.) used in the 48-h study period determined in milligram morphine equivalents. Hydrocodone and oxycodone dose was converted to i.v. milligram morphine equivalents for analysis using a standardized opioid conversion, with oral hydrocodone and oxycodone 20 mg being considered equivalent to 10 mg i.v. morphine. 7 Postoperative pain at rest and on movement (defined as sitting upright 90 degrees) was measured using a verbal NRS of 0-10 recorded at 3, 6, 12, 24, 36, and 48 h and analysed with a mixed-effects model in NONMEM (Icon Development Solutions, Ellicott City, MD, USA) as described below in the Statistical Analysis section. The duration of hospital stay was defined as hours from the end of surgery and to hospital discharge. A satisfaction score with analgesia (0 ¼ totally unsatisfied and 100 ¼ totally satisfied) was requested at 24 and 48 h post-CD. Opioid-related side effects, including pruritus, nausea, and vomiting, were recorded at 3, 6, 24, 36, and 48 h after surgery. Nausea was assessed using a verbal NRS of 0-10, with 0 ¼ no nausea and 10 ¼ the worst nausea you can imagine; vomiting was assessed as yes or no and the number of episodes per 24-h period; pruritus was assessed using a verbal NRS of 0-10, with 0 ¼ no itching and 10 ¼ the worst itching you can imagine. The extent of nausea and pruritus was analysed as an area under the curve (AUC) over 48 h [NRS (0-10) Â time (h)]. Nausea and vomiting were treated with ondansetron 4 mg and/or metoclopramide 10 mg. Pruritus was treated with nalbuphine 2.5 mg and/or diphenhydramine 25 mg. Rescue medication for nausea, vomiting, and pruritus was analysed as the number of medication doses administered.
Statistical analysis
The primary outcome measure was the amount of supplemental opioid analgesic medication (oral and i.v.) used in the 48-h study period determined in milligram morphine equivalents. An a priori power analysis predicted that we required 120 study subjects (60 subjects per study arm) to detect a clinically meaningful 33% difference in milligram morphine equivalents of opioid analgesic consumption over the 48-h study postoperative period (power-
The expected effect size and variance were based on previous data collected at our institution and estimates from the literature. 6 8 Analyses were done on an intent-to-treat basis using all women who met inclusion criteria and who received the ITM dose.
Descriptive statistics and graphical analysis were performed on all study data to assess distributions. Demographic and outcome data are summarized with descriptive statistics and expressed as the mean (SD), median [interquartile range (IQR)], or number (percentage) as appropriate. Potential associations between patient choice and demographic variables were evaluated using Student's t-test for normally distributed variables and Mann-Whitney U-test for nonparametric comparisons. Associations among discrete variables were investigated using v 2 test and Fisher exact test, where appropriate. Associations between pain at rest with movement, nausea, pruritus and patient satisfaction were analysed using least-squares regression and the Pearson correlation coefficient as reported. Covariates were not included to assess their effect per se or adjust for imbalance among groups, but were included if significant associations with the outcome were observed. This approach was utilized to minimize covariate variability and to gain efficiency. No additional covariates were entered into the final model. Pain (verbal NRS) and the amount of opioid analgesics (i.v. milligram morphine equivalents) required for breakthrough pain were considered continuous variables. Longitudinal primary outcomes are presented with the Bayesian fit and 95% confidence intervals (CIs) calculated in NONMEM with PLT Tools (PLTsoft, San Francisco, CA, USA). These values are non-parametric and do not assume a normal distribution of data. The fit can be considered similar to a median, with data weighted by interindividual variability. Time series analysis of pain and opioid rescue was performed with mixed-effects models. This allows separation of fixed effects (e.g. patient-perceived choice, morphine dose) from random effects. The random effects were bifurcated into interindividual (between subject) variability and intra-individual (within subject or 'residual') variability. The model structure permits estimates of the fixed effects based on all observations without a requirement for imputation of missing data, as previously described for analgesic trials. 9 We did not impose a mathematical structure for the relationship of pain or opioid use over time. Instead, the mathematical relationship consisted of x and y data pairs, where x was the intended time of the observation and y was the observed response. The prediction of y included an estimated nominal magnitude, a fixed effect for choice, a fixed effect for other included variables (such as dose, a random effect shared across all y values for that individual), and a random effect for the response (that was unique to the subject-response pair). The random effects were drawn from a normal distribution, with a mean of 0 and a variance of x 2 (interindividual effect) or r 2 (intra-individual effect). Loglikelihood difference was used to compare models. Final parameter estimates were considered significant at P-values <0.05 with a two-sided a after adjustment for multiple comparisons.
Estimates of parameters are reported as 'typical values' and can be interpreted as approximately the median value. CIs were calculated using log-likelihood profiles using PLT Tools. Loglikelihood profiles were graphed to examine the parameter estimate vs. P-value based on the v 2 distribution. Non-time series data were evaluated using R, version 3.1.2 (R Foundation for Statistical Computing, Vienna, Austria; http://www.R-project. org). We evaluated the severity of nausea and pruritus as the AUC, as these data were zero inflated.
Results
Fifteen women approached refused enrolment in the study and three women were unable to consent due to already being enrolled in a conflicting study. Three women recruited were withdrawn (emergency CD, CD requiring general anaesthesia, and patient changed her mind) and were replaced. A total of 120 women were enrolled and all completed the study (n ¼ 59 in the perceived-choice group and n ¼ 61 in the no-choice group). Data from all these patients were included in the analysis. Figure 1 shows a breakdown of the randomization of women offered a perceived choice of ITM 100 or 200 lg and actually receiving the dose. Note that women in the perceived-choice group were actually randomly assigned to 100 lg (n ¼ 31) or 200 lg (n ¼ 28) ITM.
In the no-choice group, the patients were not offered a choice and were similarly randomly assigned a dose of 100 lg (n ¼ 32) or 200 lg (n ¼ 29) ITM. Demographic and obstetric characteristics data for the study cohort are presented in Table 1 . None of the variables in Table 1 were significantly associated with the choice of lower or higher ITM dose. Seventy-five percent of the study cohort had undergone a previous CD. The median number of previous CDs was 1 (IQR 0-1), with no significant difference among study groups (P > 0.05).
Effect of offering patients a choice of dose on analgesia and side effects
Being offered a choice of ITM dose did not affect the opioid requirements for breakthrough pain [8% reduction (95% CI À1-17)] in each (3, 6, 12, 24, 36 , and 48 h) recorded dose interval (P ¼ 0.08). The median 48-h rescue opioid requirements was 25 mg and 20 mg morphine equivalents in the perceived-choice and no-choice groups, respectively (P ¼ 0.90). Rest pain was slightly less [À0.4 (95% CI À0.6 to À0.1) NRS points] in patients who were offered a choice compared with those who were not offered a perceived choice (P ¼ 0.03). Movement pain was not significantly different [À0.2 (95% CI À0.1-0.5) NRS points] in those who were offered a perceived choice of dose (P ¼ 0.31). The severity of nausea (P ¼ 0.35) and pruritus (P ¼ 0.10) measured as the AUC (data not shown) and the incidence of treatment for pruritus (18 vs. 21%; P ¼ 0.46) or nausea (36 vs. 46%; P ¼ 0.35) were not impacted by being offered a perceived dose choice.
Relationship between dose selected, opioid requirement, pain experience, and side effects Patients who requested the larger ITM dose required 0.8 (95% CI 0.4-1.3; P < 0.001) mg morphine equivalents more opioid for breakthrough pain at each (3, 6, 12, 24, 36, and 48 h) recorded dose interval than patients who requested the smaller ITM dose. The median opioid requirements in the 48-h study period was 25 and 16 mg morphine equivalents in patients who requested the larger and smaller ITM dose, respectively. Patients who preferred the lower (100 lg) dose reported 1.2 (95% CI 0.5-1.9) NRS points lower pain scores on movement compared with patients who preferred the higher (200 lg) dose, regardless of the dose actually received ( Fig. 2A and B ; P ¼ 0.0008). Pain scores at rest were similar among women who preferred 100 lg compared to 200 lg [NRS change À0.3 (95% CI À0.8-0.1); P ¼ 0.08]. There were no differences in pain at rest (P ¼ 0.82), with movement (P ¼ 0.06) or opioid rescue (P ¼ 0.23) detected in the subgroups who received their preferred dose and those who did not (data not shown).
Patients who preferred 100-lg ITM reported a similar severity of pruritus as those who preferred the higher dose ( Fig. 2C and  D) , and the incidence of treatment for pruritus (7 vs. 16%; P ¼ 0.46) was not impacted by the dose preferred. While there were no differences in reported nausea and vomiting between patients who preferred the lower or higher dose of ITM (23 vs. 28%; P ¼ 0.41), the incidence of treatment for nausea and vomiting (20 vs. 9%; P ¼ 0.01) was higher in those who preferred the lower dose of medication.
The most common reason offered for preferring the lower dose was fear of nausea and vomiting after surgery, and the most common reason for preferring the higher dose was fear of pain after surgery (Table 2 ).
Pharmacologic effect of the ITM dose given
Request for opioid rescue medication was not different according to the dose of ITM actually administered [0.3 (95% CI À0.1-0.6) milligram morphine equivalents between the 100 and 200 lg ITM groups; P ¼ 0.16]. Women treated with 200-lg ITM instead reported slightly higher pain scores at rest [0.4 (95% CI 0.1-0.6) NRS units; P ¼ 0.003] compared with patients who were treated with 100-lg ITM. Pain scores with movement were not different according to the ITM dose administered [0.3 (95% CI À0.01-0.6) NRS units; P ¼ 0.08]. The incidences of nausea (42 vs. 15%; P ¼ 0.0005) and vomiting (20 vs. 8%; P ¼ 0.007) were higher in those given 200-lg compared with 100-lg ITM. The intensity of nausea and pruritus was also higher in patients treated with 200-lg than in those treated with 100-lg ITM (Fig. 3) .
There was no difference in the duration of hospital stay between patients given 100 
Discussion
The key finding from this study is that patients are able to provide useful input on intrathecal opioid requirements for CD. We found that when offered a perceived choice of ITM dose, women could correctly anticipate their analgesic needs and likelihood of side effects. Specifically, those who preferred a larger analgesic dose correctly anticipated greater pain after CD and required more rescue opioid for breakthrough pain. Women who preferred a smaller analgesic dose had similar scores for nausea and pruritus but required more treatment for nausea and vomiting. The most common reason for dose choice cited by women who preferred the smaller ITM dose was fear of nausea, with only one patient reporting fear of pruritus as a rationale for preferring the lower dose of ITM. Interestingly, merely being offered a choice did not affect opioid dose requirements, suggesting that it was the actual choice itself and not just being given a choice that mattered.
Traditional postoperative pain management entails using standardized 'one-size-fits-all' management protocols and selecting analgesic drugs and doses to manage surgical pain without extensive patient consultation or involvement. These results establish the feasibility and potential benefit of seeking input from patients regarding their preference of appropriate analgesic doses as part of a patient-centred care model. Patient input can facilitate individualized perioperative analgesic treatment protocols based on the patient's preferences, needs, and expectations.
Postoperative pain after CD is described as moderate to severe, equivalent to that reported after abdominal hysterectomy. 10 Despite increased emphasis on pain management and the creation of new standards for controlling postoperative pain, many patients continue to experience significant pain after surgery. 11 12 The obstetric pain experience is a complex psychophysical response to care that involves cognitive (6) 33 (4) 33 (8) 34 (5) 32 (5) 32 ( (5) 23 (6) 26 (6) 25 (6) 25 (5) 25 (5) Gestational age (wk)* 39 (2) 39 (1) 39 (2) 39 (1) 39 (1) 39 (1) (14) 2 (14) 4 (29) 1 (6) 8 (25) 9 (31) evaluation and emotional response. Maternal satisfaction with analgesia is multidimensional and, importantly, includes the assessed difference between actual and expected care. 13 14 A patient's assessment of the quality of care and possibly satisfaction rating is impacted by a number of factors, including physician respect for the patient's values, preferences, and needs; quality of care; provider communication; and the patient's involvement in clinical decisions. [15] [16] [17] Future studies are required to determine if using patients to help estimate their opioid requirement and assess their aversion to opioid-related side effects can improve their postoperative pain experience and reduce rescue opioid requirements postoperatively. A patient's preference for a higher or lower dose provides easily acquired and important information that can be included in the physician's algorithm for treatment recommendations. A reduction in maternal opioid use after CD is beneficial to both mother and nursing infants. Maternal side effects from opioid exposure are well described, 18 and opioids transfer to breast milk is potentially avoided. 19 20 We did not identify a difference in nausea, vomiting, or pruritus in the patients not offered compared with those offered a perceived choice of ITM dose; however, we may have been underpowered to detect this secondary outcome. A large body of literature has tried to preoperatively identify patients at risk of developing severe postoperative pain and having higher analgesic dose requirements. The hope behind preoperative pain prediction is to allow clinicians to offer patients deemed to be at high risk of developing severe postoperative pain individualized or targeted analgesic treatment plans. Given 100 For example, patients undergoing CD could prophylactically receive larger ITM doses and/or additional adjunctive medications such as gabapentin, ketamine, or clonidine. Drugs and doses that would otherwise not routinely be useful in all patients for CD due to their side effect profiles could be utilized in selected 'high-risk' patients. 21 22 Current standardized surgical pain management protocols may lead to undertreatment in patients with high analgesic needs and overtreatment (increased side effects from analgesics) in patients with low analgesic needs.
To date, our ability to predict pain and then apply modified treatment protocols has been limited. Studies have found that patient's preoperative responses to experimental pain tests are variable, with 4-54% of postoperative pain variance predicted. 23 Psychological characteristics such as anxiety, fear of pain, and pain catastrophizing measured by validated questionnaires also explain only a small percentage of postoperative pain variance. 21 24 The association of genetic variables with human pain sensitivity has also been limited, probably due to the phenotype of pain perception and analgesic requirements being complex, multifactorial, and subjective and the genotyping being polygenic and complex. 25 Our study findings suggest that patients'
input on analgesic dose preference may be a useful resource to facilitate preoperative prediction of postoperative pain. Concern for nausea and vomiting after surgery was the overwhelming reason for women preferring the low ITM dose, and fear of pain after surgery was the key reason for patient's preference for the higher ITM dose. Our study cohort with a median age in the 30s would likely have experienced painful events and surgical interventions and had analgesic needs and side effects before participation in this study. We hypothesize that their past pain and analgesic side effect experience would have helped guide them to understand their individual CD pain and opioid needs. Although we did record a reason for the women's dose preference, we did not evaluate past surgical or painful events to determine if these events specifically influenced a patient's ITM dose selection, pain, and/or opioid used after CD.
We did not observe the expected pharmacologic analgesic effect of the dose actually given. There was no difference in pain or opioid use among women who actually received the 100-or 200-lg ITM doses. Although some studies have shown a difference in analgesia provided by these different ITM doses, 6 8 26 a number of studies have found no significant differences in pain and opioid use with increasing ITM doses ranging from 100 to 250 lg. [26] [27] [28] [29] [30] The likely reason for modest differences in these doses is that there is an analgesic ceiling with ITM doses and beyond 100 lg is the flat part of the dose vs clinical effect curve. We selected these doses, as we have utilized and evaluated both doses at our institution and understand the analgesic and side effect characteristics of these ITM doses. 6 These dose choices also allowed us to ethically use deception, as these two doses are known to have clinical efficacy and no excess of severe side effects in our population. We have found that both ITM doses are safe and have relatively small differences in their efficacy and side effects, 6 26 therefore, deception would be of negligible consequence. We did not receive any complaints or feedback from women who were informed that they were deceived, so we cannot comment on the consequences of deception on a participant's subsequent willingness to participate in future research.
As an expected pharmacologic effect, we found significantly more opioid-related side effects with the 200-lg dose than with the 100-lg dose. Higher ITM doses are generally associated with increasing opioid-related side effects, although this dose effect is variable among clinically utilized doses. 6 8 26 Concern for nausea and vomiting after surgery was the overwhelming reason for the low ITM dose preference in the women offered an ITM dose choice. There was no difference in nausea, vomiting, or pruritus according to the preferred dose, although those who requested a lower dose required more rescue treatment for nausea and vomiting. The trade-off of analgesic efficacy and related side effects suggests that combining knowledge of known pharmacologic dose responses with patient preference for anticipated pain and analgesic needs may be the optimal approach for surgical pain treatment.
There are potentially a number of limitations to this study. ITM impacts pain predominantly in first 24 h, such that we would not expect to see a large difference in opioid consumption or pain scores in that time period. However, as the study period was 48 h, differences in pain and rescue medication would be apparent in the 24-48-h period. 8 26 We appreciate that the analgesic efficacy and side effect trade-off script would have some influence on the women's ITM dose selection. We aimed to minimize this influence by providing a standardized script that was read by a single researcher (F.M.). The script was evidence based and reflects experience with analgesic and side-effect responses in patients treated at our institution. 6 We expect generalizability of our study results, as we used ITM doses commonly used for CD analgesia in the USA 3 ; however, we appreciate different patient demographics at other institutions that may influence the reproducibility of our findings. We acknowledge that the study may have been underpowered to detect a pharmacologic effect within the perceived-choice group. It is possible that the higher (200 lg) ITM dose as requested in those given a perceived choice might have led to improved pain outcome. An increased shoulder of the dose-response curve for patients at high risk for severe postoperative pain has been suggested. 31 In conclusion, our study demonstrates that women given a choice who preferred the larger analgesic dose correctly anticipated greater opioid use and pain after their CD and less need for rescue treatment for nausea and vomiting. This study demonstrates the importance of considering a patient's ITM dose preference in conjunction with the known pharmacologic doseresponse relationship for analgesia and opioid side effects. The study further establishes the feasibility of patient involvement in selecting appropriate analgesic doses and protocols as part of patient-centred care and may facilitate individualized or stratified perioperative analgesic treatment protocols based on patients' analgesic medication preferences. Patient-led dose selection (based on their individual preferences for pain relief and side effects after surgery) may compensate for interindividual response variability when standardized postoperative treatment protocols are used, and may provide a method to preoperatively identify patients with the greatest postoperative pain and analgesic needs. Future studies are required to determine if individualized patient-selected pain treatment protocols significantly improve postoperative pain management for patients undergoing surgery.
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